MedTrace Logo

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

NCT03749187 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2026-03-13

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma.

Conditions

  • Glioblastoma
  • IDH1 Gene Mutation
  • IDH2 Gene Mutation
  • Low Grade Glioma
  • Malignant Glioma
  • Recurrent Glioblastoma
  • Recurrent WHO Grade II Glioma
  • Recurrent WHO Grade III Glioma
  • WHO Grade II Glioma
  • WHO Grade III Glioma

Interventions

DRUG

PARP Inhibitor BGB-290

Given PO

DRUG

Temozolomide (TMZ)

Given PO

Sponsors & Collaborators

Principal Investigators

  • Sabine Mueller, MD, PhD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-03
Primary Completion
2026-06-30
Completion
2029-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03749187 on ClinicalTrials.gov